MESO Mesoblast Pharma: Forward P/S Multiple

Corporate company logo of Mesoblast Limited (MESO)

Mesoblast Limited (MESO) is implementing a strategy to bring innovative cell-based therapies to market, and on GURU.Markets, this linear chart of the forward P/S ratio demonstrates a long-term trend where the metric holds at 14.10. High production scalability potential at low costs is combined with flawlessly optimized cold-chain logistics, ensuring stable global distribution of biomedical products.

MESO mesoblast.com: Price-to-Projected Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Mesoblast Limited

- market price and analyst price targets:
Price Chart Mesoblast|MESO - Average Forecast Price
- company stock capitalization data:
Market Capitalization Mesoblast Pharma|MESO - Total Company Value
- issuer book value statistics:
Net Assets per Single Share Mesoblast|MESO - Company Book Value|Market Capitalization to Book Value Ratio mesoblast.com|MESO - Company Total Assets
- business debt structure and liquidity details:
Debt to Equity Mesoblast Limited|MESO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Mesoblast Limited|MESO - Company Cumulative Indebtedness|Debt to Book Value Mesoblast Pharma|MESO - Company Long-Term Loans and Borrowings|Company Short-Term Debt Mesoblast|Quick Ratio mesoblast.com
- business earnings and investment ratios data:
MESO - Net Financial Result|Expected Profit Mesoblast Limited|MESO - Price to Earnings Ratio|Forward P/E Multiple Mesoblast Corp|MESO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Mesoblast Pharma|MESO - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Mesoblast|MESO - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth mesoblast.com|MESO - Earnings per share growth this year|Net earnings per share growth forecast for next year Mesoblast Limited
- sales revenue and business income indicators:
MESO - Company Sales|Projected Sales Volume Mesoblast|MESO - Price to Sales|Price-to-Projected Revenue Ratio Mesoblast Pharma
General company analysis:Mesoblast (MESO)
Original product of mesoblast.com

The forward P/S multiple determines the investment attractiveness of Mesoblast Limited (MESO) by comparing current market capitalization with expected revenue, which helps identify the risk of asset overvaluation if forecasts are not met. This chart reflects market expectations regarding the commercialization of developments, which for a non-cyclical biotech business depends not on macroeconomic factors, but exclusively on the success of clinical trials for unique cellular products.

Key competitors

Price-to-Projected Revenue Ratio Lineage Cell Therapeutics, Inc. LCTX|Surrozen Inc (SRZN) - Market Cap to Future Revenue Ratio|Cryo-Cell International Inc - Forward P/S Multiple|FBLG: Price-to-Projected Revenue Ratio|Longeveron Inc. (LGVN) - Price-to-Projected Revenue Ratio|BRTX (BioRestorative Therapies, Inc.) - Price-to-Projected Revenue Ratio|CELZ (Creative Medical Technology Holdings, Inc.) - Forward P/S Multiple